A double-blind, randomized, placebo-controlled phase II study investigated recombinant MAGE-A3 protein combined with an immunostimulant in completely resected MAGE-A3–positive stage IB to II NSCLC patients. This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.